Small Group Discussion On Biotech Careers - Monday, Jan 13th at 1PM

Dr. Ken Blount, cofounder and director of biology at BioRelix Inc., will lead an one-hour discussion on Monday, January 13th at 1pm, location TBA. 

There are eight open slots for this event.  Please email Tenaya Vallery (tenaya.vallery@yale.edu) to secure a spot.  

Career Mentor's Bio: Dr. Ken Blount earned his Ph.D. at the University of Colorado, studying the mechanisms of RNA enzymes (ribozymes).  He went onto an NIH Post-Doctoral Fellowship at the University of California at San Diego, studying RNA-targeting small-molecular antibiotics.  In 2004, he contacted Ron Breaker at Yale regarding Ron's interest in forming a startup focused on developing antibiotics that target RNA riboswitches.  In 2005, he joined Ron's team, leading the effort to found BioRelix.  BioRelix secured seed-round investment in 2006 and Series A investment in 2007 and is currently developing novel antibiotics that target riboswitches.  BioRelix has also formed a research collaboration with Merck Pharmaceuticals to leverage the unique riboswitch target portfolio.